Scynexis (SCYX) EBITDA Margin (2013 - 2025)
Scynexis (SCYX) posted EBITDA Margin of 56.42% for Q4 2025, up 102.24% on a QoQ basis from 2516.47% in Q3 2025, and up 88068.0% year-over-year from N/an in Q4 2024.
Scynexis (SCYX) EBITDA Margin (2013 - 2025) Analysis & Trends
Scynexis' EBITDA Margin history runs 12 years deep, the most recent figure standing at 56.42% for Q4 2025.
- Quarterly EBITDA Margin rose 88068.0% year-over-year to 56.42% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 119.86% (up 125733.0% YoY) and the FY2025 annual result came in at 78.03%, up 91282.0% from the prior year.
- EBITDA Margin was 56.42% for Q4 2025 at Scynexis, up from 2516.47% in the prior quarter.
- Across five years, EBITDA Margin topped out at 88.63% in Q2 2023 and bottomed at 3767.64% in Q3 2021.
- A 5-year average of 1448.86% and a median of 1255.03% in 2024 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 236744 bps in 2022, while the deepest fall reached 280649 bps in 2022.
- Scynexis' EBITDA Margin stood at 3734.84% in 2021, then soared by 61 bps to 1475.13% in 2022, then surged by 73 bps to 397.88% in 2023, then slumped by 107 bps to 824.26% in 2024, then jumped by 107 bps to 56.42% in 2025.
- Business Quant data shows SCYX's EBITDA Margin at 56.42% in Q4 2025, 2516.47% in Q3 2025, and 700.95% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 56.42% |
| Sep 30, 2025 | -2,516.47% |
| Jun 30, 2025 | -700.95% |
| Mar 31, 2025 | -3,350.19% |
| Dec 31, 2024 | -824.26% |
| Sep 30, 2024 | -1,563.64% |
| Jun 30, 2024 | -1,255.03% |
| Mar 31, 2024 | -692.50% |
| Dec 31, 2023 | -397.88% |
| Sep 30, 2023 | -573.42% |
| Jun 30, 2023 | 88.63% |
| Mar 31, 2023 | -945.31% |
| Dec 31, 2022 | -1,475.13% |
| Sep 30, 2022 | -1,400.19% |
| Jun 30, 2022 | -1,643.08% |
| Mar 31, 2022 | -2,819.71% |
| Dec 31, 2021 | -3,734.84% |
| Sep 30, 2021 | -3,767.64% |
| Mar 31, 2021 | -13.23% |
| Jun 30, 2019 | -19,642.11% |